NERLYNX (neratinib) immediate release, film-coated tablets for oral administration contain 40 mg of neratinib, equivalent to 48.31 mg neratinib maleate. Neratinib is a member of the 4-anilino quinolidine class of protein kinase inhibitors. Inactive ingredients: Tablet Core: colloidal silicon dioxide, mannitol, microcrystalline cellulose, crospovidone, povidone, magnesium stearate & purified water. Coating: red film coat: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, iron oxide red.
NERLYNX (neratinib) Tablets: 40 mg.
Recommended dosage: 240 mg (6 tablets) given orally once daily with food, continuously for one year. • Dose interruptions and/or dose reductions are recommended based on individual safety and tolerability. • Hepatic Impairment: Reduce starting dose to 80 mg in patients with severe hepatic impairment.
NERLYNX (neratinib) is a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.
